Emergent BioSolutions Inc. (EBS) — SEC Financial Statements & Analysis

Emergent BioSolutions Inc. (EBS) is a pharmaceutical preparations company, incorporated in DE. Emergent BioSolutions Inc. trades on NYSE as: EBS. Emergent BioSolutions Inc. (EBS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Emergent BioSolutions Inc. carries a market cap of $432.41M, a P/E ratio of -2.45x, a P/B ratio of 1.27x, a P/S ratio of 0.56x, an enterprise value of $873.31M, and an EV/EBITDA multiple of 30.75x. On profitability, it posts a gross margin of 55.87%, an operating margin of -8.57%, a net margin of -22.96%, a Return on Equity (ROE) of -40.29%, a Return on Assets (ROA) of -13.95%, and a Return on Invested Capital (ROIC) of -7.55%. Per share, it reports EPS of $-3.43, diluted EPS of $-3.43, free cash flow per share of $1.66, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -9.56% year-over-year, net income growth of -226.74% year-over-year, and EPS growth of -233.12% year-over-year. On the balance sheet, it maintains a current ratio of 5.42x, a quick ratio of 2.74x, working capital of $543.20M, a debt-to-equity ratio of 2.27x, a debt ratio of 0.69, an interest coverage ratio of -1.30x, free cash flow of $85.90M (TTM), and net debt of $440.90M. Figures sourced from SEC EDGAR.

Market Cap

$432.41M

P/E TTM

-2.45x

EPS TTM

$-3.43

P/B TTM

1.27x

ROE TTM

-40.29%

ROA TTM

-13.95%

Debt To Equity

2.27x

Free Cash Flow TTM

$85.90M

Net Revenue TTM Growth 1Y

-9.56%

Data as of 2026-06-30 · Source: SEC EDGAR